evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

7 questions · 7 findings · 3 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 4 · 57.1%Low 3 · 42.9%Moderate 0 · 0%High 0 · 0%

Standard‐dose VKA plus single antiplatelet agent vs one antiplatelet agent

Stroke · people with antiphospholipid syndrome, with previous stroke

It is very uncertain whether standard‐dose VKA plus single antiplatelet agent changes stroke compared with single antiplatelet agent (very low certainty).

1 finding from 1 review

Standard‐dose VKA plus single antiplatelet agent vs dual antiplatelet agent

Stroke · people with antiphospholipid syndrome, with previous stroke

It is very uncertain whether standard‐dose VKA plus single antiplatelet agent changes stroke compared with dual antiplatelet agent (very low certainty).

1 finding from 1 review

Antiplatelet agent vs control

Fatal or nonfatal stroke · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)

It is very uncertain whether antiplatelet agents changes fatal or nonfatal stroke compared with control (very low certainty).

1 finding from 1 review

Standard‐dose VKA plus single antiplatelet agent vs vitamin K antagonist (VKA)

Strokea · people with antiphospholipid syndrome and a history of stroke or thromboembolic events

Standard‐dose VKA plus single antiplatelet agent showed no clear difference in strokea compared with standard‐dose VKA (low certainty).

1 finding from 1 review